Feld, Ronald

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

Hughes, W. T., Armstrong, D., Bodey, G. P., Bow, E. J., Brown, A. E., Calandra, T., Feld, R., Pizzo, P. A., Rolston, K. V. I., Shenep, J. L., et al. (2002) · Clinical Infectious Diseases

Neutropenia and Cancer InfectionsAntifungal resistance and susceptibility

Cited by 1,964

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Garassino, M. C., Cho, B.-C., Kim, J.-H., Mazières, J., Vansteenkiste, J., Lena, H., Corral Jaime, J., Gray, J. E., Powderly, J., Chouaid, C., et al. (2018) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 568

Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials

Di Maio, M., Gallo, C., Leighl, N. B., Piccirillo, M. C., Daniele, G., Nuzzo, F., Gridelli, C., Gebbia, V., Ciardiello, F., De Placido, S., et al. (2015) · Journal of Clinical Oncology

Cancer survivorship and carePharmacovigilance and Adverse Drug Reactions

Cited by 497

Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC)

Labbé, C., Cabanero, M., Korpanty, G. J., Tomasini, P., Doherty, M. K., Mascaux, C., Jao, K., Pitcher, B., Wang, R., Pintilie, M., et al. (2017) · Lung Cancer

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 230

Evolution of symptom burden of advanced lung cancer over a decade

Sung, M. R., Patel, M. V., Djalalov, S., Le, L. W., Shepherd, F. A., Burkes, R. L., Feld, R., Lin, S., Tudor, R., & Leighl, N. B. (2017) · Clinical Lung Cancer

Cancer survivorship and carePalliative Care and End-of-Life Issues

Cited by 98